



an Open Access Journal by MDPI

Advances in Urothelial Cancer

Guest Editors:

Dr. Ho Kyung Seo

Department of Urology,
Chonnam National University
Medical School, Chonnam
National University Hwasun
Hospital, Gwangju, Republic of
Korea

Prof. Dr. Eu Chang Hwang

Department of Urology,
Chonnam National University
Medical School, Chonnam
National University Hwasun
Hospital, Gwangju, Republic of
Korea

Dr. Whi-An Kwon

Department of Urology, Myongji
Hospital, Hanyang University
College of Medicine, 55, Hwasu-
ro, 14 beon-gil, Deogyang-gu,
Gyeonggi-do, Goyang-si 10475,
Republic of Korea

Deadline for manuscript
submissions:

closed (30 November 2022)



mdpi.com/si/109622

Message from the Guest Editors

Recent advances in genomics technologies have classified molecular subtypes of bladder cancer based on gene expression profiling and have examined their significance in clinical utility to inform prognosis and/or to predict therapeutic responses.

The use of immune checkpoint inhibitors, particularly with antibodies directed against programmed cell death 1 protein (PD-1) or its ligand (PD-L1), has led to important advances in the treatment of metastatic urothelial cancer and been tested in the early stages of bladder cancer. However, only a small number of patients respond to checkpoint inhibitors. Therefore, attempts are being made to develop biomarkers that could help to identify urothelial cancer patients who are likely to respond to these drugs.

As a type of targeted therapy, therapeutic agents such as enfortumab vedotin, an antibody-drug conjugate designed to treat Nectin-4 expressing cancer, and erdafitinib, a small molecule inhibitor of fibroblast growth factor receptor, have been accepted in clinical studies on metastatic bladder cancer.



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPlus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
X@Biomed_MDPI